GJA1 and neoplasm: Targeting Cx43 channels may offer a novel therapeutic strategy for overcoming immune resistance, and combining immune checkpoint inhibition with Cx43-mediated gap junction regulation could improve tumor response to immunotherapy and enhance anti-tumor immune responses.